Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology

BACKGROUND: Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer’s disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evidence suggests that post-translationally modified Aβ peptides might play a deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Gnoth, Kathrin, Piechotta, Anke, Kleinschmidt, Martin, Konrath, Sandra, Schenk, Mathias, Taudte, Nadine, Ramsbeck, Daniel, Rieckmann, Vera, Geissler, Stefanie, Eichentopf, Rico, Barendrecht, Susan, Hartlage-Rübsamen, Maike, Demuth, Hans-Ulrich, Roßner, Steffen, Cynis, Holger, Rahfeld, Jens-Ulrich, Schilling, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666770/
https://www.ncbi.nlm.nih.gov/pubmed/33189132
http://dx.doi.org/10.1186/s13195-020-00719-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666770/
https://www.ncbi.nlm.nih.gov/pubmed/33189132
http://dx.doi.org/10.1186/s13195-020-00719-x

Ejemplares similares